- Quarterly Report (10-Q)

Share Name	Share Symbol	Market	Type
Omnimmune Holdings Inc (CE)	USOTC:OMMH	OTCMarkets	Common Stock

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended March 31, 2009.

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from _________to _________.

Commission File Number: 333-145507

OMNIMMUNE HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		26-3128407
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)


4600 Post Oak Place, Suite 352 , Houston , Texas		77027
(Address of principal executive offices)		(Zip Code)

(713) 622-8400

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( § 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o

Accelerated filer o

Non-accelerated filer o

Smaller reporting company x

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of May 19, 2009 there were 8,814,921 shares of the issuer’s common stock outstanding.

Table of Contents

OMNIMMUNE HOLDINGS, INC. and Subsidiaries

Quarterly Report on Form 10-Q

TABLE OF CONTENTS

		Page

	PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements	4
	Consolidated Balance Sheets as of March 31, 2009 and December 31, 2008	4
	Consolidated Statements of Operations for the three months ended March 31, 2009 and March 31, 2008	5
	Consolidated Statement of Stockholders’ Deficiency as of March 31, 2009	5
	Consolidated Statements of Cash Flows for the three months ended March 31, 2009 and March 31, 2008	18
	Notes to Consolidated Financial Statements	20
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	31
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	35
Item 4.	Controls and Procedures	35

	PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	36
Item 1A.	Risk Factors	36
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3.	Defaults Upon Senior Securities	37
Item 4.	Submission of Matters to a Vote of Security Holders	37
Item 5.	Other Information	37
Item 6.	Exhibits	38

Table of Contents

EXPLANATORY NOTE

Unless otherwise indicated or the context otherwise requires, all references below in this Current Report to “we,” “us,” “our” and the “Company” are to Omnimmune Holdings, Inc., a Delaware corporation. Omnimmune Holdings, Inc. was originally incorporated on February 22, 2007, in the State of Nevada under the name Roughneck Supplies, Inc., and upon a merger with and into Omnimmune Holdings, Inc. effective August 6, 2008, the Company changed its domicile to Delaware. Further, on August 7, 2008, Omnimmune Corp., a Texas corporation, merged with and into the Company’s wholly owned subsidiary and Delaware corporation, Omnimmune Acquisition Corp., after which Omnimmune Acquisition Corp. changed its name to Omnimmune Corp. (the “Merger”). Prior to the Merger, the Company was a shell company and Omnimmune Corp. was considered the acquirer for accounting purposes in the transaction. As a result the historical financial statements included in this report are those of Omnimmune Corp., the Texas corporation. Unless otherwise indicated, all financial and business information contained in this Current Report relates exclusively to the business and financial affairs of Omnimmune Holdings, Inc. and its subsidiaries.

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

CONSOLIDATED BALANCE SHEETS

	March 31,			December 31,
	2009				2008
Assets	(Unaudited)				(Audited)
Current assets
Cash and cash equivalents	$	2,359			$	52,615

Total current assets	$	2,359			$	52,615

Liabilities and stockholders' deficiency
Current liabilities
Accounts payable and accrued liabilities	$	722,738			$	471,775
Line of credit		256,568				259,157
Accrued interest		186,889				192,380
Cash advance		110,000				100,000
Notes payable - current portion , net		437,046				-
Accounts payable and accrued liabilities-related party		360,000				351,748
Accrued interest- related party		477,616				424,210
Notes payable due to related parties, net		-				287,768

Total current liabilities		2,550,857				2,087,038

Long term portion of notes payable - net		562,534				709,035
Long term portion of notes payable, due to related parties, net		1,001,318				1,000,864

Total liabilities		4,114,709				3,796,937

Commitments and contingencies		-				-

Stockholders' deficiency
Common stock, $0.0001 par value; 50,000,000 shares authorized;
8,814,921 shares issued and outstanding
for both periods		880				880
Additional paid-in capital		15,603,198				15,592,797
Deficit Accumulated during the Development Stage		(19,716,428	)			(19,337,999	)
Total stockholder's deficit		(4,112,352	)			(3,744,322	)

	$	2,359			$	52,615

See notes to consolidated financial statements.

Table of Contents

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended March 31,			For the Three Months Ended March 31,			Cumulative from Inception (January 15, 1997) to March 31,
	2009			2008			2009
Revenue	$	-		$	-		$	-

Operating expenses:
General and administrative expenses		321,741			430,126			12,838,750
Impairment of license agreement		-			-			1,701,936
Total operating expenses		321,741			430,126			14,540,686

Operating loss		(321,741	)		(430,126	)		(14,540,686	)

Other expense:
Interest (income) expense, net		56,688			6,707,853			11,592,891
Cancellation of shares previously issued for license agreement		-			-			(842,514)
Gain on restructuring of debt		-			(5,677,726	)		(5,574,635	)
Total other (income) expense		(56,688	)		(1,030,127	)		(5,175,742	)

Loss before taxes		(378,429	)		(1,460,253	)		(19,716,428	)

Provision for taxes		-			-			-

Net loss	$	(378,429	)	$	(1,460,253	)	$	(19,716,428	)

Net loss per share - basic and diluted	$	(0.04	)	$	(0.50	)

Weighted average shares outstanding - basic and diluted		8,814,926			2,938,888

See notes to consolidated financial statements.

Table of Contents

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIENCY

	Preferred Stock						Common Stock
	Shares		Value		Additional Paid-in Capital		Shares		Value		Additional Paid-in Capital		Common Stock Subscribed		Accumulated Deficit			Total Stockholders Equity
Balance at January 15, 1997 (date of inception)		-	$	-	$	-		-	$	-	$	-	$	-	$	-		$	-

Contribution of assets and liabilities by founder		11,229		112		49,888		1,055,507		106		43,466		-		-			43,572

Beneficial conversion feature of note payable for the year ended December 31, 1997		-		-		-		-		-		327,700		-		-			327,700

Loss for the year ended December 31, 1997		-		-		-		-		-		-		-		(1,366,300	)		(1,366,300	)

Balance as of December 31, 1997		11,229	$	112	$	49,888		1,055,507	$	106	$	371,166	$	-	$	(1,366,300	)	$	(945,028	)

Beneficial conversion feature of note payable for the year ended December 31, 1998		-		-		-		-		-		43,000		-		-			43,000

Loss for the year ended December 31, 1998		-		-		-		-		-		-		-		(328,534	)		(328,534	)

Balance as of December 31, 1998		11,229	$	112	$	49,888		1,055,507	$	106	$	414,166	$	-	$	(1,694,834	)	$	(1,230,562	)

Table of Contents

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIENCY

(Continued)

	Preferred Stock						Common Stock
	Shares		Value		Additional Paid-in Capital		Shares		Value		Additional Paid-in Capital		Common Stock Subscribed		Accumulated Deficit		Total Stockholders Equity
Issuance of 55,553 shares of common stock for technology license at $1.10 per share		-		-		-		55,553		5		61,837		-		-		61,842

Issuance of 5,614 shares of convertible preferred stock at $4.45 per share to investors		5,614		56		24,944		-		-		-		-		-		25,000

Issuance of 5,614 shares of convertible preferred stock at $4.45 per share to investors		5,614		56		24,944		-		-		-		-		-		25,000

Issuance of 5,614 shares of convertible preferred stock at $4.45 per share to investors		5,614		56		24,944		-		-		-		-		-		25,000

Issuance of 5,614 shares of convertible preferred stock at $4.45 per share to investors		5,614		56		24,944		-		-		-		-		-		25,000

Beneficial conversion feature of note payable for the year ended December 31, 1999		-		-		-		-		-		12,000		-		-		12,000

Table of Contents

	Preferred Stock						Common Stock
	Shares		Value		Additional Paid-in Capital		Shares		Value		Additional Paid-in Capital		Common Stock Subscribed		Accumulated Deficit			Total Stockholders Equity
Loss for the year ended December 31, 1999	-		-		-			-		-		-		-		(429,692	)		(429,692	)

Balance as of December 31, 1999		33,685	$	336	$	149,664		1,111,060	$	111	$	488,003	$	-	$	(2,124,526	)	$	(1,486,412	)

Issuance of 5,614 shares of convertible preferred stock at $4.45 per share to investors		5,614		56		24,944		-		-		-		-		-			25,000

Issuance of 11,229 shares of convertible preferred stock at $4.45 per share to investors		11,229		112		49,888		-		-		-		-		-			50,000

Issuance of 5,614 shares of convertible preferred stock at $4.45 per share to investors		5,614		56		24,944		-		-		-		-		-			25,000

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-			6,250

Beneficial conversion feature of note payable for the year ended December 31, 2000		-		-		-		-		-		30,302		-		-			30,302

Loss for the year ended December 31, 2000		-		-		-		-		-		-		-		(422,306	)		(422,306	)

Balance as of December 31, 2000		56,142	$	560	$	249,440		1,113,867	$	111	$	524,555	$	-	$	(2,546,832	)	$	(1,772,166	)

Table of Contents

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIENCY

(Continued)

	Preferred Stock						Common Stock
	Shares		Value		Additional Paid-in Capital		Shares		Value		Additional Paid-in Capital		Common Stock Subscribed		Accumulated Deficit		Total Stockholders Equity
Issuance of 1,055,507 shares of common stock at $2.24 per share in exchange for 2,500,000 shares in InVitro technology		-		-		-		1,055,507		107		59,894		-		-		60,001

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-		6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-		6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-		6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-		6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-		6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-		6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-		6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-		6,250

Table of Contents

	Preferred Stock						Common Stock
	Shares		Value		Additional Paid-in Capital		Shares		Value		Additional Paid-in Capital		Common Stock Subscribed		Accumulated Deficit			Total Stockholders Equity
Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-			6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-			6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-			6,250

Issuance of 2,807 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		2,807		-		6,250		-		-			6,250

Issuance of 60,665 shares of common stock at $2.24 per share for a technology license		-		-		-		60,665		7		135,060		-		-			135,067

Issuance of 5,614 shares of convertible preferred stock at $4.45 per share to investors		5,614		56		24,944		-		-		-		-		-			25,000

Issuance of 5,614 shares of convertible preferred stock at $4.45 per share to investors		5,614		56		24,944		-		-		-		-		-			25,000

Issuance of 7,018 shares of common stock at $2.24 per share to a consultant for services rendered		-		-		-		7,018		2		15,624		-		-			15,626

Value of 14,036 warrants issued to consultants		-		-		-		-		-		15,500		-		-			15,500

Beneficial conversion feature of note payable for the year ended December 31, 2001		-		-		-		-		-		25,000		-		-			25,000

Loss for the year ended December 31, 2001		-		-		-		-		-		-		-		(959,531	)		(959,531	)

Balance as of December 31, 2001		67,370	$	672	$	299,328		2,270,741	$	227	$	850,633	$	-	$	(3,506,363	)	$	(2,355,503	)

Table of Contents

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIENCY

(Continued)

	Preferred Stock						Common Stock
	Shares			Value			Additional Paid-in Capital			Shares		Value		Additional Paid-in Capital		Common Stock Subscribed		Accumulated Deficit		Total Stockholders Equity
Issuance of 1,123 shares of convertible preferred stock at $4.45 per share to investors		1,123			11			4,989			-		-		-		-		-		5,000

Conversion of 11,229 shares convertible preferred stock into 44,915 shares of common stock at $2.24 per share		(11,229	)		(112	)		(49,888	)		44,915		4		49,996		-		-		-

Conversion of 5,614 shares convertible preferred stock into 11,229 shares of common stock at $2.22 per share		(5,614	)		(56	)		(24,944	)		11,229		2		24,998		-		-		-

Conversion of 5,614 shares convertible preferred stock into 11,229 shares of common stock at $2.22 per share		(5,614	)		(56	)		(24,944	)		11,229		2		24,998		-		-		-

Conversion of 5,614 shares convertible preferred stock into 11,229 shares of common stock at $2.22 per share		(5,614	)		(56	)		(24,944	)		11,229		1		24,999		-		-		-

Conversion of 16,843 shares convertible preferred stock into 33,686 shares of common stock at $2.24 per share		(16,843	)		(56	)		(74,832	)		33,686		3		74,997		-		-		-

Table of Contents

	Preferred Stock									Common Stock
	Shares			Value			Additional Paid-in Capital			Shares		Value		Additional Paid-in Capital		Common Stock Subscribed		Accumulated Deficit			Total Stockholders Equity
Conversion of 16,843 shares convertible preferred stock into 33,686 shares of common stock at $2.24 per share		(16,843	)		(168	)		(74,832	)		33,686		3		74,997		-		-			-

Conversion of 5,614 shares convertible preferred stock into 11,229 shares of common stock at $2.22 per share		(5,614	)		(168	)		(24,944	)		11,229		1		24,999		-		-			-

Conversion of 1,123 shares convertible preferred stock into 2,246 shares of common stock at $2.24 per share		(1,122	)		(11	)		(4,989	)		2,246		-		5,000		-		-			-

Beneficial conversion feature of note payable for the year ended December 31, 2002		-			-			-			-		-		1,175,356		-		-			1,175,356

Loss for the year ended December 31, 2002		-			-			-			-		-		-		-		(3,061,599	)		(3,061,599	)

Balance as of December 31, 2002		-		$	-		$	-			2,430,190	$	243	$	2,330,973	$	-	$	(6,567,962	)	$	(4,236,746	)

Table of Contents

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIENCY

(Continued)

	Preferred Stock						Common Stock
	Shares		Value		Additional Paid-in Capital		Shares		Value		Additional Paid-in Capital		Common Stock Subscribed		Accumulated Deficit			Total Stockholders Equity
Beneficial conversion feature of note payable for the year ended December 31, 2003		-		-		-		-		-		29,401		-		-			29,401

Loss for the year ended December 31, 2003		-		-		-		-		-		-		-		(540,986	)		(540,986	)

Balance as of December 31, 2003		-	$	-	$	-		2,430,190	$	243	$	2,360,374	$	-	$	(7,108,948	)	$	(4,748,331	)

Issuance of 1,404 shares of common stock at $2.24 to a consultant for services rendered		-		-		-		1,404		-		3,125		-		-			3,125

Issuance of 1,404 shares of common stock at $2.24 to a consultant for services rendered		-		-		-		1,404		-		3,125		-		-			3,125

Value of 26,107 warrants issued to consultants		-		-		-		-		-		93,000		-		-			93,000

Beneficial conversion feature of note payable for the year ended December 31, 2004		-		-		-		-		-		17,149		-		-			17,149

Loss for the year ended December 31, 2004		-		-		-		-		-		-		-		(1,252,796	)		(1,252,796	)

Balance as of December 31, 2004		-	$	-	$	-		2,432,998	$	243	$	2,476,773	$	-	$	(8,361,744	)	$	(5,884,728	)

Issuance of 134,746 shares of common stock at $2.24 for a technology license		-		-		-		134,746		13		299,987		-		-			300,000

Issuance of 6,661 shares at $3.74 per share for cash		-		-		-		6,661		1		24,999		-		-			25,000

Beneficial conversion feature of note payable for the year ended December 31, 2005		-		-		-		-		-		72,000		-		-			72,000

Loss for the year ended December 31, 2005		-		-		-		-		-		-		-		(1,141,448	)		(1,141,448	)

Balance as of December 31, 2005		-	$	-	$	-		2,574,405	$	257	$	2,873,759	$	-	$	(9,503,192	)	$	(6,629,176	)

Table of Contents

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIENCY

(Continued)

	Preferred Stock						Common Stock
	Shares		Value		Additional Paid-in Capital		Shares		Value		Additional Paid-in Capital		Common Stock Subscribed		Accumulated Deficit			Total Stockholders Equity
Issuance of 4,913 pursuant to an antidilution agreement		-		-		-		4,913		-		-		-		-			-

Issuance of 1,235 pursuant to an antidilution agreement		-		-		-		1,235		-		-		-		-			-

Issuance of 1,235 pursuant to an antidilution agreement		-		-		-		1,235		-		-		-		-			-

Issuance of 1,235 pursuant to an antidilution agreement		-		-		-		1,235		-		-		-		-			-

Issuance of 3,706 pursuant to an antidilution agreement		-		-		-		3,705		-		-		-		-			-

Issuance of 3,706 pursuant to an antidilution agreement		-		-		-		3,705		-		-		-		-			-

Issuance of 1,235 pursuant to an antidilution agreement		-		-		-		1,235		-		-		-		-			-

Issuance of 225 pursuant to an antidilution agreement		-		-		-		225		-		-		-		-			-

Beneficial conversion feature of note payable for the year ended		-		-		-		-		-		4,000		-		-			4,000

Loss for the year ended December 31, 2006		-		-		-		-		-		-		-		(1,076,266	)		(1,076,266	)

Table of Contents

Preferred Stock

Common Stock

Value

Additional Paid-in Capital

Value

Additional Paid-in Capital

Common

Stock

Subscribed

Accumulated

Deficit

Total Stockholders

Equity

Balance at December 31, 2006	-	$	-	$	-	2,591,893	$	257	$	2,877,759		$	-		$	(10,579,458	)	$	(7,701,442	)

Issuance of 7,018 shares at $3.74 per share for services rendered	-		-		-	7,017		2		26,249			-			-			26,251

Issuance of 25,989 shares for $3.74 per share for licensing agreement	-		-		-	25,988		2		97,204			-			-			97,206

Issuance of 25,989 shares for $3.74 per share for licensing agreement	-		-		-	25,990		2		97,204			-			-			97,206

119,053 shares to be issued at $0.37 per share for license agreement	-		-		-	-		-		-			445,305			-			445,305

119,053 shares to be issued at $0.37 per share for license agreement	-		-		-	-		-		-			445,305			-			445,305

Beneficial conversion feature of note payable for the year ended December 31, 2007	-		-		-	-		-		6,604,430			-			-			6,604,430

Loss for the year months ended December 31, 2007	-		-		-	-		-		-			-			(2,768,669	)		(2,768,669	)

Balance at December 31, 2007	-	$	-	$	-	2,650,888	$	263	$	9,702,846		$	890,610		$	(13,348,127	)	$	(2,754,408	)

Recapitalization upon reverse merger	-		-		-	3,000,000		300		(300	)		-			-			-

Issuance of 119,053 shares of common stock at $0.37 per share, previously accrued	-		-		-	119,053		12		445,293			(445,305	)		-			-

Table of Contents

Preferred Stock

Common Stock

Value

Additional Paid-in Capital

Value

Additional Paid-in Capital

Common

Stock

Subscribed

Accumulated

Deficit

Total Stockholders

Equity

Issuance of 119,053 shares of common stock at $0.37 per share, previously accrued	-	-	-	119,053	12	445,293	(445,305	)	-	-

Issuance of 1,055,507 shares of common stock for cash at a price of $0.011 per share	-	-	-	1,055,508	106	44,690	-		-	44,796

Issuance of 100,000 shares of common stock and 20,000 warrants to purchase additional shares of common stock at a price of $0.05 per share as a discount on notes payable	-	-	-	100,000	10	55,991	-		-	56,001

Issuance of 1,055,508 shares of common stock at a price of $0.03 per share to a board member for services	-	-	-	1,055,507	105	29,895	-		-	30,000

Issuance of 150,000 shares of common stock at a price of $1.25 per share to officers for services	-	-	-	150,000	15	187,485	-		-	187,500

Issuance of 137,500 shares of common stock at a price of $0.05 per share as a discount to notes payable	-	-	-	137,500	14	6,861	-		-	6,875

Table of Contents

Preferred Stock

Common Stock

Value

Additional Paid-in Capital

Value

Additional Paid-in Capital

Common

Stock

Subscribed

Accumulated

Deficit

Total Stockholders

Equity

Sale of 707,200 shares of common stock and 707,200 warrants to purchase additional shares of common stock at a price of $2.50 per share for cash, net of costs of $359,729	-		-		-	707,200			71			1,408,200			-		-			1,408,271

Cancellation of shares issued for technology license	-		-		-	(279,788	)		(28	)		(842,486	)		-		-			(842,514	)

Value of options to purchase 2,250,000 shares of common stock at a price of $2,50 per shares issued to board member for extension of payment terms	-		-		-	-			-			2,811,962			-		-			2,811,962

Value of warrants to purchase 75,000 shares of common stock at $2,50 per share issued to a board member for services	-		-		-	-			-			93,733			-		-			93,733

Value of warrants to 70,180 shares of common stock at $1,78 per share issued to a board member for extension of credit terms	-		-		-	-			-			129,278			-		-			129,278

Value of vested portion of options issued to officer	-		-		-	-			-			54,848			-		-			54,848

Discount to notes payable due to beneficial conversion feature	-		-		-	-			-			1,019,208			-		-			1,019,208

Loss for the year ended December 31, 2008	-		-		-	-			-			-			-		(5,989,872)			(5,989,872	)

Balance as of December 31, 2008	-	$	-	$	-	8,814,921		$	880		$	15,592,797		$	-	$	(19,337,999)		$	(3,744,322	)

Value of vested portion of 100,000 options issued to officer (unaudited)	-		-		-	-			-			10,401			-		-			10,401

Loss for the three months ended March 31, 2009 (unaudited)	-		-		-	-			-			-			-		(378,429	)		(378,429	)

Balance as of March 31, 2009 (unaudited)	-	$	-	$	-	8,814,921		$	880		$	15,603,198		$	-	$	(19,716,428	)	$	(4,112,350	)

See notes to consolidated financial statements.

Table of Contents

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Three Months Ended March 31, 2009			For the Three Months Ended March 31, 2008			Cumulative from Inception (January 15, 1997) to March 31, 2009
Cash flows from operating activities:
Net loss	$	(378,429	)	$	(1,460,253	)	$	(19,716,428	)
Adjustments to reconcile net loss to net
cash used in operating activities:
Non-cash compensation		10,401			-			4,016,911
Amortization of discount on notes payable		3,2318			6,476,682			8,745,650
Impairment of technology licenses and equity securities		-			-			1,701,936
Gain on restructuring of debt		-			(5,677,726	)		(5,577,000	)
Redemption of shares previously issued for license agreement		-			-			(842,513	)
Net change in operating assets and liabilities:
Advances to related party		-			-			(10,000	)
Accounts payable and accrued liabilities		307,130			358,906			7,886,980

Net cash used in operating activities		(57,667	)		(302,391	)		(3,794,464	)

Cash flows from investing activities:
Cash portion of investment in technology license		-			-			(6,000	)

Net cash used in investing activities		-			-			(6,000	)

Cash flows from financing activities:
Proceeds from cash advances		10,000			102,000			806,000
Principal payments on cash advances		-			-			(130,000	)
Stock sold for cash, net of costs		-			-			1,738,271
Proceeds from (repayments) to line of credit		(2,589	)		(2,320	)		256,571
Principal payments on debt		-			-			(512,993	)
Proceeds from notes payable		-			300,000			1,644,974

Net cash provided by financing activities		7,411			399,680			3,802,823

Net increase/ (decrease) in cash and cash equivalents		(50,256	)		97,289			2,359

Cash and cash equivalents at beginning of period		52,615			209			-

Cash and cash equivalents at end of period	$	2,359		$	97,498		$	2,359

Table of Contents

CONSOLIDATED STATEMENTS OF CASH FLOWS

(continued)

		For the Three Months Ended March 31, 2009		For the Three Months Ended March 31, 2008			Cumulative from Inception (January 15, 1997) to March 31, 2009

Supplemental disclosures of cash flow information:

Cash paid during the period for: Interest	$	3,051	$	4,862		$	67,374

Income Taxes	$	-	$	-		$	-
Items not affecting cash flows:
Beneficial conversion feature of notes payable	$	3,238	$	6,476,682		$	14,894,478

Common stock issued for services	$	-	$	-		$	317,875

Notes payable issued under restructure of debt	$	-	$	-		$	7,284,998

Value of warrant issued as discount on debt	$	-	$	129,278		$	331,510

Notes payable issued for accounts payable	$	-	$	-		$	287,768

Common stock issued for technology license	$	-	$	-		$	751,326

Common stock issued for the conversion of preferred stock	$	-	$	-		$	355,000

Notes payable issued for services	$	-	$	-		$	3,746,971

Impairment of technology licenses	$	-	$	-		$	616,908

Value of warrants issued for debt	$	-	$	-		$	12,747

Issuance of common stock for cash	$	-	$	-		$	1,408,271

Gain from the restructuring of debt	$	-	$	(5,677,726	)	$	(5,576,993	)

Value of options issued for services	$	10,401	$	-		$	2,877,210

Common stock exchanged for accounts payable	$	-	$	30,000		$	30,000

Cash advance converted to notes payable	$	-	$	-		$	521,200

Capitalization of interest on debt	$	-	$	-		$	33,751

See notes to consolidated financial statements.

Table of Contents

OMNIMMUNE HOLDINGS, INC.

(A DEVELOPMENT STAGE ENTERPRISE)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business and Basis of Presentation

The Company’s operating subsidiary, Omnimmune Corp., is currently a development stage company under the provisions of Statement of Financial Accounting Standards, (“SFAS”) No 7. The Company, whose principal business is to act as a holding company for Omnimmune Corp., is also a development-stage company. The accounts of the Company also include those of its wholly owned subsidiary, InVitro Technologies, Inc., an inactive company.

Merger with Roughneck Supplies, Inc.

The predecessor of the Company was originally incorporated on February 22, 2007, in the State of Nevada as Roughneck Supplies, Inc. (“Roughneck”). On August 6, 2008, Roughneck merged with and into Omnimmune Holdings, Inc. On August 7, 2008, Omnimmune Corp., a privately held Texas corporation incorporated on January 15, 1997 merged with and into Omnimmune Acquisition Corp., a Delaware corporation, and a wholly-owned subsidiary of the Company formed for the purpose of the merger. As a result, (i) Omnimmune Corp became a wholly-owned subsidiary of the Company, (ii) the shareholders of Omnimmune Corp. became the majority stockholders of the Company and the shareholders prior to the merger were reduced to a minority ownership, (iii) the historical management of the Company resigned, and the management of Omnimmune Corp. became the management of the Company, (iv) the business of Omnimmune Corp. became the business of Omnimmune and the former business of Roughneck was eliminated, and (v) the historical financial statements of Omnimmune Corp. became the historical financial statements of the Company. Therefore, as a consequence of the two mergers, one on August 6, 2008 and one on August 7, 2008, Omnimmune (formerly Roughneck) went from being a public corporation domiciled in Nevada formerly in the business of marketing and retailing oil and gas drilling supply products with little or no continuing operations and a fiscal year end of May 31, to being a public company domiciled in Delaware in the biotechnology business with a fiscal year end of December 31. These transactions are described in detail in the Company’s Form 8-K filed with the SEC on August 12, 2008, as amended on August 21, 2008, August 27, 2008 and September 5, 2008, respectively.

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements the Company incurred losses from operations of $378,429 and $1,460,253 for the three months ended March 31, 2009 and 2008, respectively; and $19,716,428 from inception (January 15, 1997) through March 31, 2009. In addition, the Company’s current liabilities exceed its current assets by $2,548,500 as of March 31, 2009. These factors among others, including the Company’s current cash position, which was $2,359 as of March 31, 2009, may indicate that the Company will be unable to continue as a going concern for a reasonable period of time absent the infusion of substantial additional capital.

If operations and cash flows substantially improve, including through funds realized upon a debt or equity financing transaction, management believes that the Company can meets its ongoing obligations and continue to operate. However, no assurance can be given that management’s actions will result in the resolution of its liquidity problems or its eventual emergence as a profitable company.

The accompanying consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reported periods. Actual results could materially differ from those estimates.

Table of Contents

Long-lived Assets

In accordance with SFAS No. 144, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. SFAS No. 144 relates to assets that can be amortized and the life determinable. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value of asset less the cost to sell. During the three months ended March 31, 2009, and 2008, the Company recognized $0 impairment of long-lived assets. From inception to March 31, 2009 an impairment of license agreement in the amount of $1,701,936 was recorded.

Cash and Cash Equivalents

For the purposes of the statement of cash flows, cash equivalents include highly liquid debt instruments with original maturities of three months or less which are not securing any corporate obligations.

Net Income (Loss) Per Common Share

The Company computes earnings per share under Financial Accounting Standard No. 128, "Earnings Per Share" (SFAS 128). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding during the year. Dilutive common stock equivalents consist of shares issuable upon conversion of convertible notes and the exercise of the Company's stock options and warrants (calculated using the treasury stock method). During the three months ended March 31, 2009 and 2008, and from inception to March 31, 2009, common stock equivalents were not considered in the calculation of the weighted average number of common shares outstanding because they would be anti-dilutive, thereby decreasing the net loss per common share.

At March 31, 2009, the following convertible securities were not included in fully-diluted loss per share because the result would have been anti-dilutive: Options to purchase 2,350,000 shares at $2.50 per share; Warrants to purchase 25,265 shares at $0.10 per share, warrants to purchase 70,180 shares at $1.78 per share, warrants to purchase 75,000 shares at $2.50 per share, and warrants to purchase 727,200 shares at $5.00 per share; debt convertible into 5,368,886 shares at $0.18 per share, and debt convertible into 2,000,000 shares at $0.50 per share.

At March 31, 2008, the following convertible securities were not included in fully-diluted loss per share because the result would have been anti-dilutive: Warrants to purchase 84,216 shares at $0.10 per share, warrants to purchase 70,180 shares at $1.78 per share, and warrants to purchase 15,000 shares at $5.00 per share; debt convertible into 5,705,776 shares at $0.18 per share, and debt convertible into 2,067,090 shares at $0.50 per share.

Research and Development

The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board's Statement of Financial Accounting Standards No. 2 ("SFAS 2"), "Accounting for Research and Development Costs." Under SFAS 2, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. There were no expenditures on research and product development for the three months ended March 31, 2009 and 2008, and from inception through March 31, 2009.

Concentrations of Credit Risk

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and related party receivables. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

Comprehensive Income

Statement of Financial Accounting Standards No. 130 ("SFAS 130"), "Reporting Comprehensive Income," establishes standards for reporting and displaying of comprehensive income, its components and accumulated balances. Comprehensive income is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, SFAS 130 requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. During the three months ended March 31, 2009 and 2008 there were no terms of other comprehensive income.

Table of Contents

Stock Based Compensation

Effective January 1, 2006, the Company adopted SFAS No. 123 (revised), "Share-Based Payment" (SFAS 123(R)) utilizing the modified prospective approach. Prior to the adoption of SFAS 123(R) we accounted for stock option grant in accordance with APB Opinion No. 25, "Accounting for Stock Issued to Employees" (the intrinsic value method), and accordingly, recognized compensation expense for stock option grants.

Under the modified prospective approach, SFAS 123(R) applies to new awards and to awards that were outstanding on January 1, 2006 that are subsequently modified, repurchased or cancelled. Under the modified prospective approach, compensation cost recognized in the nine months of fiscal 2006 includes compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006, based on the grant-date fair value estimated in accordance with the original provisions of SFAS 123, and compensation cost for all share-based payments granted subsequent to January 1, 2006 based on the grant-date fair value estimated in accordance with the provisions of SFAS 123(R). Prior periods were not restated to reflect the impact of adopting the new standard.

A summary of option activity under the Plan as of March 31, 2009, and changes during the period ended are presented below:

	Options		Weighted Average Exercise Price
Outstanding at December 31, 2008		2,350,000	$	2.50
Issued		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding at March 31, 2009		2,350,000	$	2.50
Vested at March 31, 2009		2,302,537	$	2.50
Non-vested at March 31, 2009		47,463	$	2.50

Aggregate intrinsic value of options outstanding and exercisable at March 31, 2009 was $0. Aggregate intrinsic value represents the difference between the Company's closing stock price on the last trading day of the fiscal period, which was $0.40 as of March 31, 2009, and the exercise price multiplied by the number of options outstanding. As of March 31, 2009, total unrecognized stock-based compensation expense related to stock options was $58,945. The total fair value of options vested during the three months March 31, 2009 and 2008 was $10,401 and $0, respectively.

Income Taxes

The Company has implemented the provisions of Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes" (SFAS 109). SFAS 109 requires that income tax accounts be computed using the liability method. Deferred taxes are determined based upon the estimated future tax effects of differences between the financial reporting and tax reporting bases of assets and liabilities given the provisions of currently enacted tax laws.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carryforwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. Realization of the deferred tax asset is dependent on generating sufficient taxable income in future years. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Due to the uncertainties as to the realization of deferred tax assets, an allowance has been provided regarding all deferred tax assets of the Company.

Fair Value of Financial Instruments

The Company measures its financial assets and liabilities in accordance with accounting principles generally accepted in the United States of America. The estimated fair values approximate their carrying value because of the short-term maturity of these instruments or the stated interest rates are indicative of market interest rates.

Reclassifications

Certain reclassifications have been made in prior year's financial statements to conform to classifications used in the current year.

Table of Contents

Foreign Currency

Aside from one of its license agreements, which requires milestone and other payments to be made in Euros, the Company is not involved any transactions with foreign currency implications.

New Accounting Pronouncements

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities.” SFAS 159 permits entities to choose to measure many financial instruments, and certain other items, at fair value. SFAS 159 applies to reporting periods beginning after November 15, 2007. The adoption of SFAS 159 is not expected to have a material impact on the Company’s financial condition or results of operations.

2. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at March 31, 2009 and December 31, 2008 of $722,738 and $471,775, respectively, consist of trade payables. Accounts payable and accrued liabilities – related parties at March 31, 2009 and December 31, 2008 of $360,000 and $351,748, respectively, consist of accrued liabilities to directors for services performed.

3. LINE OF CREDIT

The Company has bank loan and credit card agreements with various banks. The bank loan is jointly guaranteed by two of the Company’s shareholders. The Company's Chief Executive Officer, Harris Lichtenstein, co-signs the credit card agreements and remains jointly liable with the Company on all outstanding amounts due for these credit card liabilities. At March 31, 2009 and December 31, 2008, the Company had the following amounts due under its loan and credit agreement:

	March 31, 2009		December 31, 2008
Bank loan	$	149,976	$	149,976
Credit cards		106,592		109,181
Total	$	256,568	$	259,157

4. ACCRUED INTEREST

Notes payable and accrued interest at March 31, 2009 and December 31, 2008 is summarized as follows:

	March 31,		December 31,
	2009		2008
Number of notes payable		16		16
Number of notes payable - related party		4		5

Principal amount - notes payable	$	999,580	$	709,035
Principal amount - notes payable - related party	$	1,001,318	$	1,288,632

Accrued interest	$	186,889	$	192,380
Accrued interest - related party	$	477,616	$	424,210

Interest expense (net) consisted of the following for the three months ended March 31, 2009 and 2008:

	March 31,
	2009			2008
Accrued interest - notes payable	$	46,699		$	18,485
Accrued interest - notes payable – related party		1,216			77,542
Bank credit line		3,051			3,353
Amortization of discount on notes payable		3,238			6,476,682
Amortization of discount on accounts payable		-			129,278
Credit Cards		2,487			2,513
Interest (income)		(3	)		-
Total	$	56,688		$	6,707,853

Table of Contents

5. CASH ADVANCES

During the three months ended March 31, 2009, the Company received $10,000 in new non-interest bearing payable on demand, unsecured cash advances from a shareholder.

6. NOTES PAYABLE

At March 31, 2009, the Company had outstanding 16 notes payable in the aggregate principal amount of $2,943,245, none of which was in default.

The Company has convertible notes payable outstanding which contain a provision for contingent warrants that are potentially issuable. Pursuant to the convertible notes agreements, these warrants are issuable if the note holder elects to convert at least 25% of the principal amount of the note during the term of the note. At March 31, 2009, there are contingent 5 year warrants issuable to purchase an aggregate of 43,000 shares of the Company’s common stock at a price of $5.00 per share.

The following table summarizes amounts due under the notes payable at March 31, 2009 and December 31, 2008:

	Principal balance:
	March 31, 2009			December 31, 2008
Total outstanding	$	2,943,245		$	2,943,252
Less discount on notes payable		(942,347	)		(945,585	)
Net Total		2,000,898			1,997,667
Less current portion		(437,046	)		(287,768	)
TOTAL	$	1,563,852		$	1,709,899

The following table lists the notes payable at March 31, 2009 and December 31, 2008:

	Principal balance:,
	March 31, 2009		December 31, 2008
Convertible note payable to a related party in the amount of $2,000,000 dated June 14, 1994. On March 3, 2007, this note was replaced with a new note in the amount of $3,170,188, which included accrued interest in the amount of $959,089, a salary payable of $106,575, and a loss of $104,524. On March 1, 2008, this note was replaced with a new note in the amount of $500,000, the amount of $2,670,188 was forgiven by the note holder. The note signed on March 2, 2008, is a non interest bearing note, and is payable contingent upon (a) the Company’s receipt of revenues, as defined, in which case the Company will pay 2% of such revenues, as received, in satisfaction of this note; and/or (b) the sale of substantially all of the Company’s assets. Interest in the amount of $0 and $37,087 was accrued on these notes during the three months ended March 31, 2009 and 2008, respectively. Total accrued interest at March 31, 2009 and 2008 amounted to $222,521.
	$	500,000	$	500,000
Convertible note payable to a related party in the amount of $1,170,356 dated May 15, 2002. On March 3, 2007, this note was replaced with a new note in the amount of $1,342,127, which included accrued interest of $379,324, and a gain of $207,553. On March 1, 2008, this note was replaced with a new note in the amount of $500,000, the amount of $842,127 was forgiven by the debt holder. The note dated March 1, 2008 is a non interest bearing note, and is payable contingent upon (a) the Company’s receipt of revenues, as defined, in which case the Company will pay 2% of such revenues, as received, in satisfaction of this note; and/or (b) the sale of substantially all of the Company’s assets. Interest in the amount of $0 and $15,701 was accrued on these notes during the three months ended March 31, 2009 and 2008, respectively. Total accrued interest at March 31, 2009 and 2008 amounted to $94,206.
		500,000		500,000
Convertible note payable to a related party in the amount of $25,000 dated March 10, 2005. On March 3, 2007, this note was replaced with a new note in the amount of $30,211, which includes accrued interest of $4,938 and a loss of $272. On March 31, 2008, this note was replaced with a new note, which includes accrued interest of $3,021. The note bears interest at the rate of 10% per annum, and was due in full on February 28, 2013. This note is convertible into common stock of the Company at a conversion price of $0.1781 per share. A beneficial conversion feature in the amount of $33,232 was recorded as a discount to the note and is being amortized over the term of the note via the effective interest rate method at a rate of 8.3%. Interest in the amount of $819 and $779 was accrued on this note during the three months ended March 31, 2009 and 2008, respectively. Total accrued interest at March 31, 2009 and 2008 amounted to $3,605 and $282, respectively.
		33,232		33,232

Table of Contents

	Principal balance:
	March 31, 2009	December 31, 2008
Convertible note payable to a related party in the amount of $37,000 dated February 26, 2005. On March 3, 2007, this note was replaced with a new note in the amount of $44,848, which included accrued interest of $6,418, and loss of $1,430. On March 1, 2008, this note was replaced with a new note, which includes accrued interest of $4,485. The note bears interest at the rate of 10% per annum, and is due in full on February 1, 2013. This note is convertible into common stock of the Company at a conversion price of $1.78 per share. A beneficial conversion feature in the amount of $49,333 was recorded as a discount to the note, and is being amortized over the term of the note via the effective interest rate method at a rate of 8% Interest in the amount of $1,216 and $1,156 was accrued on this note during the three months ended March 31, 2009 and 2008, respectively. Total accrued interest at March 31, 2009 and 2008 amounted to $5,352 and $419, respectively.
	49,333	49,333
Note payable in the amount of $8,110 dated December 31, 1997. On March 3, 2007, this note was replaced with a new note in the amount of $19,442, which included accrued interest of $7,437, and loss of $3,895. The note bears interest at the rate of 10% per annum, and is due in full on February 28, 2010. Interest in the amount of $479 and $485 was accrued on this note during the three months ended March 31, 2009 and 2008, respectively. Total accrued interest at March 31, 2009 and 2008 amounted to $4,054 and $2,109, respectively. During the period ended December 31, 2008, the Company exercised its right to extend the maturity date until February 28, 2010.
	19,442	19,442
Note payable in the amount of $11,932 dated December 31, 1999. On March 3, 2007, this note was replaced with a new note in the amount of $23,641, which included accrued interest of $8,168, and a loss of $3,540. The note bears interest at the rate of 10% per annum, and is due in full on February 28, 2010. Interest in the amount of $583 and $589 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $4,929 and $2,565, respectively. During the period ended December 31, 2008, the Company exercised its right to extend the maturity date until February 28, 2010.
	23,641	23,641
Note payable in the amount of $33,860 dated December 31, 2000. On March 3, 2007, this note was replaced with a new note in the amount of $60,971, which included accrued interest of $20,882, and a loss of $6,228. The note bears interest at the rate of 10% per annum, and is due in full on February 28, 2010. Interest in the amount of $1,503 and $1,520 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $12,712 and $6,615, respectively. During the period ended December 31, 2008, the Company exercised its right to extend the maturity date until February 28, 2010.
	60,971	60,971
Note payable in the amount of $25,000 dated February 28, 2001. On March 3, 2007, this note was replaced with a new not in the amount of $44,355, which included accrued interest in the amount of $15,014, and a loss of $4,341. On March 1, 2008, this note was replaced with a new note in the amount of $127,305, which consolidated two other notes payable to this note holder in the amounts of $41,774, and $28,603, and accrued interest of $11,573.The note bears interest at the rate of 10% per annum, and is due in full on February 28, 2013. This note is convertible into shares of common stock at a rate of $1.78 per share. A beneficial conversion in the amount of $127,305 was recorded for this note and is being amortized over the term of the note via the effective interest rate method at a rate of 8.2%. Interest in the amount of $3,139 and $1,810 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $13,812 and $1,081, respectively.
	127,305	127,305
Note payable in the amount of $16,750 dated June 1, 2002. On March 3, 2007, this note was replaced with a new note in the amount of $45,224, which included accrued interest in the amount of $14,275, and a loss of $3,322. The note bears interest at the rate of 10% per annum, and is due in full on February 28, 2010. Interest in the amount of $1,115 and $1,128 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $9,429 and $4,906, respectively. During the period ended December 31, 2008, the Company exercised its right to extend the maturity date until February 28, 2010.
	45,224	45,224
Note payable in the amount of $18,000 dated June 1, 2002. On March 3, 2007, this note was replaced wit ha new note in the amount of $28,350, which included accrued interest in the amount of $8,551, and a loss of $1,798. On March 1, 2008, a new note replaced with a new note in the amount of $31,185, which includes accrued interest in the amount of $2,835. The note bears interest at the rate of 10% per annum, and is due in full on February 28, 2013. This note is convertible into shares of common stock at a rate of $1.78 per shares. A beneficial conversion feature in the amount of $31,285 was recorded for this note and is being amortized over the term of the note via the effective interest rate method at a rate of 8.3%. Interest in the amount of $769 and $734 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $3,383 and $265, respectively.
	31,185	31,185

Table of Contents

	Principal balance:
	March 31, 2009	December 31, 2008
Note payable in the amount of $62,019 dated July 1, 2005. On January 1, 2007, this note was replaced with a new note in the amount of $94,334, which included accrued interest of $9,328, and a loss of 422,987. On March 1, 2008, a new note replaced this note in the amount of $91,149, which includes accrued interest in the amount of $2,221. The note bears interest at the rate of 10% per annum, and is due in full on February 28, 2013. This note is convertible into shares of common stock at a price of $1.78 per share. A beneficial conversion feature was recorded in the amount of $91,149 on the note. Interest in the amount of $2,173 and $2,183 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $8,812 and $0, respectively.
	88,132	88,139
Note payable in the amount of $25,000 dated October 6, 2005. On March 3, 2007, this note was replaced with a new note in the amount of $28,603, which included interest in the amount of $3,500, and a loss of $103. On March 1, 2008, this note was consolidated into a new note, shown above. Interest in the amount of $716 and $680 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $3,184 and $246, respectively.
	29,025	29,025
Note payable in the amount of $69,806 dated March 3, 2007. On March 1, 2008, this note was replaced with a new note in the amount of $76,787, which included accrued interest in the amount of $6,981. The note bears interest at a rate of 10% per annum, and is due in full on February 28, 2013. This note is convertible into shares (post shares) of common stock at a rate of $1.78 per share. A beneficial conversion feature in the amount of $76,787 was recorded on the note and is being amortized over the term of the note via the effective interest rate method at a rate of 8.3%. Interest in the amount of $1,893 and $1,740 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $8,272 and $593, respectively.
	76,787	76,787
Note payable in the amount of $550,000 dated June 24, 2008. The note bears interest at a rate of 10% per annum, and is due in full on June 24, 2010. This note becomes convertible into shares of common stock upon the closing of a qualified financing. Interest in the amount of $13,562 and $0 was accrued during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $42,192 and $0, respectively.
	550,000	550,000
Note payable in the amount of $521,200 dated March 1, 2008. The note bears interest at a rate of 10% per annum, and is due in full on February 28, 2013. This note is convertible into common stock at a rate of $1.78 per share. A beneficial conversion feature in the amount of $521,200 was recorded and is being amortized over the term of the note via the effective interest rate method at a rate of 8.3%. Interest in the amount of $12,852 and $4,777 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $59,724 and $4,777, respectively.
	521,200	521,200
Note payable in the amount of $287,768 dated October 31, 2008. The note bears interest at a rate of 10% per annum, and is due in full on June 30, 2009. Interest in the amount of $7,096 and $0 was accrued on this note during the three months ended March 31, 2009 and 2008. Total accrued interest at March 31, 2009 and 2008 amounted to $11,905 and $0, respectively.
	287,768	287,768

Total outstanding	$	2,943,245		$	2,943,252
Less discount on notes payable		(942,347	)		(945,585	)
Total – net of discounts		2,000,898			1,997,667
Less current portion – net of discounts		(437,046	)		(287,768	)
Long-term portion – net of discounts	$	1,563,852		$	1,709,899

Related Party		1,001,318			1,288,632
Related Party – current portion		-			287,768
Related Party – long term portion	$	1,001,318		$	1,000,864

Non-related party	$	999,580		$	709,035
Non-related party – current portion		437,046			-
Non-related party – long term portion	$	562,534		$	709,035

Table of Contents

7. EQUITY

On July 8, 2008, the Company filed an amendment to its certificate of incorporation in the State of Delaware amending the number of authorized shares from 300,000,000 to 50,000,000 and the par value from $0.01 to $0.0001. At December 31, 2008 and December 31, 2007, the Company had issued and outstanding 8,814,921 and 2,650,892 shares of common stock, respectively. No shares of preferred stock are issued or outstanding.

The Company completed a 1-for-2.8072 split of its common stock, effective March 27, 2008. The Company completed a 10-for-1 reverse split of its common stock effective June 9, 2008. Each of these stock splits is accounted for in all share numbers included in this report, unless otherwise indicated.

Warrants

The following table summarizes the changes in warrants outstanding and the related prices for the shares of the Company’s common stock issued to non-employees of the Company. The following table summarizes the warrants outstanding as of March 31, 2009:

Warrants Outstanding				Warrants Exercisable
Exercise Prices		Number Outstanding	Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Remaining Contractual Life (years)
$	0.10	25,265	0.29	$	0.10	25,265	0.29
	1.78-2.50	145,180	6.67		1.78-2.50	145,180	6.67
5.00		727,200	4.36		5.00	727,200	4.36
Total		897,645	4.62			897,645	4.62

Warrants Outstanding				Warrants Exercisable
Exercise Prices		Number Outstanding	Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Remaining Contractual Life (years)
$	0.10	84,215	0.21	$	0.10	84,215	0.21
	1.78-2.50	145,180	6.92		1.78-2.50	145,180	6.92
5.00		727,200	4.61		5.00	727,200	4.61
Total		956,595	4.57			956,595	4.57

Transactions involving warrants are summarized as follows:

	Number of Shares			Weighted Average Price Per Share
Outstanding at December 31, 2008		956,596		$	4.14
Granted		-			-
Exercised		-			-
Cancelled or expired		(58,951	)		0.10
Outstanding at March 31, 2009		897,645		$	4.40

Table of Contents

The Company has convertible notes payable outstanding which contain a provision for contingent warrants that are potentially issuable. Pursuant to the convertible notes agreements that warrants are issuable if the notes holder elects to convert at least 25% of the principal amount due, during the term of the note. According to the convertible note payable agreements there are warrants issuable to purchase 120,710 shares of common stock. Upon issuance these warrants are exercisable for 5 years at a price of $1.80 per share.

Options

During the year ended December 31, 2008, the Company issued unvested options to purchase 100,000 shares of common stock at a price per share of $2.50. These options were valued at an aggregate of $124,192, and vest at the following rate: 33,000 vested at the time of issuance, and the balance vest over a 23 month period. During the three months ended March 31, 2009, the Company charged to operations the fair value of the vested options, or $10,401.

The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to non-employees of the Company. The following table summarizes the warrants outstanding as of March 31, 2009:

Options Outstanding					Options Exercisable
Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Remaining Contractual Life (years)
$	2.50		2,350,000	9.02	$	2.50	2,302,537	9.02
Total			2,350,000	9.02			2,302,537	9.02

Options Outstanding					Options Exercisable
Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Remaining Contractual Life (years)
$	2.50		2,350,000	9.27	$	2.50	2,285,791	9.27
Total			2,350,000	9.27			2,285,791	9.27

Transactions involving warrants are summarized as follows:

	Number of Shares		Weighted Average Price Per Share
Outstanding at December 31, 2008		2,350,000	$	2.50
Granted		-		-
Exercised		-		-
Cancelled or expired		-		-
Outstanding at March 31, 2009		2,350,000	$	2.50
Exercisable at March 31, 2009		2,302,537	$	2.50
Not exercisable at March 31, 2009		47,463	$	2.50

Table of Contents

8. RELATED PARTIES

Amounts due to related parties at March 31, 2009 consisted of the following:

Convertible Notes Payable to related parties

The Company has a note payable outstanding to its Chief Executive Officer, in the amount of $500,000 at March 31, 2009 and December 31, 2008. The note is a non interest bearing note, and is payable contingent upon (a) the Company’s receipt of revenues, as defined, in which case the Company will pay 2% of such revenues, as received, in satisfaction of this note; and/or (b) the sale of substantially all of the Company’s assets. During the three months ended March 31, 2009 and 2008, the Company accrued no interest on these notes.

The Company has a convertible note payable outstanding to Dennis Lichtenstein, a relative of the Chief Executive Officer, in the amount of $49,333 at March 31, 2009 and December 31, 2008. The note bears interest at a rate of 10% per annum. During the three months ended March 31, 2009 and 2008, the Company accrued interest in the amount of $1,216 and $1,156, respectively. beneficial conversion feature in the amount of $49,333 was recorded as a discount to the note, and is being amortized over the term of the note via the effective interest rate method at a rate of 8%. As of March 31, 2009 a discount in the amount of $48,545 remained on this note.

The Company has a note payable outstanding to Alexander Krichevsky, an officer of the Company, in the amount of $500,000 at March 31, 2009 and December 31, 2008. The note is a non interest bearing note, and is payable contingent upon (a) the Company’s receipt of revenues, as defined, in which case the Company will pay 2% of such revenues, as received, in satisfaction of this note; and/or (b) the sale of substantially all of the Company’s assets. During the three months ended March 31, 2009 and 2008, the Company accrued no interest on these notes.

The Company has a note payable outstanding to Jennie Fay Lichtenstein, a relative of the Chief Executive Officer, in the amount of $33,232 at March 31, 2009 and December 31, 2008. This note bears interest at a rate of 10% per annum. During the three months ended March 31, 2009 and 2008, the Company accrued interest in the amount of $819 and $779, respectively. . A beneficial conversion feature in the amount of $33,232 was recorded as a discount to the note and is being amortized over the term of the note via the effective interest rate method at a rate of 8.3%. As of March 31, 2009, a discount in the amount of $32,702 remained on this note.

Accounts Payable- related parties

The Company had a liability with a director for consulting fees payable in the amount of $360,000 at March 31, 2009.

9. COMMITMENTS AND CONTINGENCIES

Lease of office space

The Company leases office space in Houston, Texas under a month to month lease calling for annual rent of $8,400 per year.

ASRI License Agreement

The Company entered into a license agreement (the “ASRI License Agreement”) with Allegheny-Singer Research Institute (“ASRI”) on February 3, 1999, as amended. The two parties agreed to an amended and restated agreement which became effective February 1, 2005. ASRI granted the Company rights to develop, manufacture, sell, rent or lease Licensed Products in the Field (each as defined in the ASRI License Agreement). The Company agreed to pay royalties of 1-2% of net sales of all products covered in the agreement. The ASRI License Agreement gives the Company the right to sublicense to third parties. The Company agreed to pay ASRI between 5-20% of the sublicense income depending on the nature of the sublicense.

The Company and ASRI agreed to further amend the ASRI License Agreement which amendment became effective February 1, 2007. As part of the amendment, ASRI granted the Company an extension on the first payment of licensing fees from the original due date of February 1, 2007 to May 1, 2007. During the three months ended March 31, 2008, the Company issued 119,053 shares of common stock previously accrued, and has issued a total of 145,042 shares of common stock under this agreement.

The Company and ASRI agreed to further amend the license agreement, which amendment became effective June 30, 2008. ASRI granted the Company an extension of the second payment of licensing fees from the original due date of February 1, 2008 to June 30, 2008. Thereafter, ASRI agreed to further extend from February 1, 2009 to August 1, 2009, the license fee of $50,000. As of March 31, 2009, the Company has paid $50,000 in licensing fees under this agreement. The Company is current in its obligations under the ASRI License Agreement, as extended.

Table of Contents

Columbia License Agreement

The Company entered into a license agreement (the “Columbia License Agreement”) with Columbia University (“Columbia”) that was effective February 1, 2005, pursuant to which Columbia granted the Company rights to develop, manufacture, sell, rent or lease Licensed Products in the Field (each as defined in the Columbia License Agreement). Columbia received a 5% equity stake in the Company. In addition, the Company paid a nonrefundable license fee of $30,000. The agreement provided that $15,000 was to be paid 60 days from the effective date of the agreement and the other $15,000 to be paid one year from the effective of the agreement. The Company agreed to reimburse Columbia for past expenses of $50,000, of which $25,000 has been paid and the other $25,000 is due after sales of the licensed products amount to $1,000,000. The Company agreed to pay royalties of 1-2% of net sales of all products covered in the agreement. The agreement gives the Company the right to sublicense to third parties. The Company agreed to pay Columbia between 10-20% of the sublicense income depending on the nature of the sublicense. The Company agreed to pay annual license maintenance fees according to the schedule below:

$10,000 during the fiscal year ended December 31, 2007

$20,000 during the fiscal year ending December 31, 2008

$35,000 during the fiscal year ending December 31, 2009

$50,000 on or before February 1, 2010; and $40,000 each year thereafter.

During the three months ended March 31, 2008, the Company issued 119,053 shares of common stock previously accrued, and has issued a total of 145,042 shares of common stock under the Columbia License Agreement.

During the year ended December 31, 2008, the Company entered into an amendment to the Columbia License Agreement, pursuant to which Columbia terminated the Stock Purchase agreement. As a result, the Company cancelled 279,788 shares of common stock, which had been previously issued to Columbia. Also during the year ended December 31, 2008, the Company and Columbia agreed to further amend the Columbia License Agreement which amendment became effective June 30, 2008. The annual license maintenance fees have been amended to the schedule shown below:

$52,500 due on or before May 1, 2009

$75,000 due on or before May 1, 2010

$60,000 due on May 1 each year thereafter

Columbia and the Company recently agreed to a further amendment to the Columbia License Agreement, pursuant to which the $52,500 license maintenance fee due on May 1, 2009 was split into two equal payments of $26,250, the first of which continued to be due on May 1, 2009, and the second of which was extended to August 1,2009. The Company has not made the required payment of $26,250 that was due on May 1, 2009, nor has it received a formal extension from Columbia with respect thereto. However, Columbia has not, as of the date of this report, declared a default under the Columbia License Agreement, after which we would have a contractual period in which to make such payment and cure the default before the Columbia License Agreement could be terminated.

IGR

The Company entered into a licensing agreement with Institut Gustave Roussy (IGR) that was effective November 1, 2007 (the “IGR License Agreement”). IGR granted the Company rights to use the Licensed Patents, Licensed Material and Licensed Information (each as defined in the IGR License Agreement). The Company agreed to pay a one time license fee of €125,000, of which €25,000 was payable on the effective date, €50,000 was payable one year from effective date and €50,000 is due two years from effective date. In addition, the Company agreed to pay license maintenance fees according to the schedule below:

€10,000 during the fiscal year ending December 31, 2008

€20,000 during the fiscal year ending December 31, 2009

€35,000 during the fiscal year ending December 31, 2010

€50,000 on or before November 1, 2011 and €50,000 every year thereafter

During the year ended December 31, 2007, the Company paid $36,087 (approximately €25,000).

In accordance with the above described schedule, on November 1, 2008, the Company was obligated to pay a total of €60,000 to IGR in license fees and maintenance fees, which payments were not made. The Company and IGR agreed to modify the payment schedule described above, so that the €10,000 would continue to be due as originally scheduled (subject to issuance of an invoice by IGR), and the license fee €50,000 otherwise due on November 1, 2008, became payable in two equal installments of €25,000 on March 1, 2009 and June 1, 2009, respectively. The €10,000 license fee was timely paid on December 1, 2008.

Thereafter, IGR agreed to split the €25,000 payment that would otherwise have been due on March 1, 2009, into two payments, the first of which was in the amount of €15,000 and continued to be due in March 2009. The second payment of €10,000 became due no later than June 2009. The Company paid to IGR €12,000 of the €15,000 that was due in March, and expects to pay the balance of €3,000 in the near term. Upon such payment, the Company will be current with IGR under the IGR License Agreement. However, the Company has no formal agreement with IGR to extend the €3,000 payment, nor does it have currently available funds with which to pay the forthcoming payment of €25,000 due in June 2009. However, IGR has not, as of the date of this report, declared a default under the IGR License Agreement, after which we would have a contractual period in which to make such payment and cure the default before the IGR License Agreement could be terminated.

Table of Contents

Ohio State Licensing Agreement

The Company entered into a licensing agreement (the “OSU License Agreement”) with Ohio State University (OSU) that was effective April 18, 2008, pursuant to which OSU granted the Company rights to use the Licensed Patents, Licensed Material and Licensed Information (each as defined in the OSU License Agreement). The Company agreed to pay a one time license fee of $300,000, of which $5,000 was paid on execution, $45,000 was paid on the first business day following the Phase 1 Data Review Period, $50,000 was paid three months after first payment, $100,000 was due November 15, 2008, $50,000 is due June 30, 2009, and $50,000 is due September 30, 2009. In addition, the Company agreed to reimburse OSU for its patent expenses according to the schedule below:

$12,738 payable in eight quarterly payments beginning October 1, 2009

As of March 31, 2009, the Company has paid $300,000 in licensing fees under this agreement.

With respect to the license fee of $100,000 that would otherwise have been due on November 15, 2008, the parties agreed that $10,000 was due in November 2008, which payment was timely made, $40,000 was due on March 1, 2009 and the balance of $50,000 would be due on June 30, 2009. In addition, the $50,000 license fee that would have been due on June 30, 2009 was extended until September 30, 2009. Interest shall accrue on all payments not made according to the original schedule. The Company failed to make the payment to OSU of the $40,000 license fee that was due on March 1, 2009. However, OSU has not, as of the date of this report, declared a default under the OSU License Agreement, after which we would have a contractual period in which to make such payment and cure the default before the OSU License Agreement could be terminated.

Contingent warrants issuable

The Company has convertible notes payable outstanding which contain a provision for contingent warrants that are potentially issuable. Pursuant to the convertible notes agreements that warrants are issuable if the notes holder elects to convert at least 25% of the principal amount due, during the term of the note. According to the convertible note payable agreements, there are potentially 1,207,096 warrants issuable to purchase shares of common stock. Upon issuance these warrants are exercisable for 5 years at a price of $0.1781 per share.

Table of Contents

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Omnimmune Holdings, Inc. (“Omnimmune” or the “Company”) is the holding company of Omnimmune Corp., a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic and prognostic technologies. Our mission is to provide a comprehensive and personalized approach to the clinical management of cancer through improved diagnostic, prognostic and therapeutic interventions. Omnimmune has acquired licensed rights to breakthrough platform monoclonal antibody technologies and a multivalent cancer vaccine targeting two epitopes of HER-2, validated tumor associated antigens. The vaccine has completed a Phase I NCI sponsored clinical trial. Omnimmune plans to sponsor Phase II and III trials and market the vaccine in collaboration with others. We believe the core technology utilized in the development of this multivalent vaccine represents a platform for the development of additional vaccines.

Omnimmune intends to play a leading role in the development of personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization) and gene-based products, which target a hormone called human chorionic gonadotropin (“hCG”). Appropriate patient-specific passive immunotherapies will be based upon a patient’s own sequences of hCGb (human chorionic gonadotropin beta subunit), and its gene products (mRNA). HCGß and its genes have been detected in a majority of cancers studied to date, and is a well validated tumor marker. On this basis, hCG has enormous potential as a target for the diagnosis and treatment of cancer patients. The application of appropriate patient-specific immunotherapy will be based upon the genetic expression and translation of a patient’s own subunit marker(s), as determined by Omnimmune’s combined immuno-genetic cancer diagnostic and prognostic systems. An immuno-genetic companion diagnostic trial is being planned by Omnimmune, and is expected to take place during the 2009 calendar year, subject to the Company obtaining sufficient financing. Omnimmune expects that the results of that trial will be a prelude to the development of a widely applicable diagnostic system for the diagnosis, prognosis and determination of recurrence of certain cancers. Omnimmune plans to conduct a Phase I trial with its lead candidate anti-hCGb monoclonal antibodies based upon the results of the diagnostic trial.

Omnimmune believes that this customized diagnostic-therapeutic coupling approach represents a new paradigm for targeted therapy, and will significantly alter the way in which cancer patients will be managed in the future. Omnimmune’s objective is to be a leader in the implementation (reduction to practice) of previously discovered and characterized vaccines and monoclonal antibodies, and in the discovery, development and commercialization of new monoclonal antibodies for diagnostic, prognostic and therapeutic (passive immunization) purposes, as well as gene-based products targeting hCGb.

Omnimmune’s unique HER-2 vaccine, hCGß and related technologies, which are protected through an expanding intellectual property portfolio, have been developed at institutions including The Ohio State University, Columbia University of New York, The Allegheny-Singer Research Institute of the Allegheny General Hospital, Pittsburgh, Pennsylvania and The Institute Gustave Roussy, Paris, France.

The predecessor of the Company was originally incorporated on February 22, 2007, in the state of Nevada as Roughneck Supplies, Inc. (“Roughneck”). On August 6, 2008, Roughneck merged with and into Omnimmune Holdings, Inc. which resulted in (i) Roughneck changing its domicile from Nevada to Delaware, (ii) Roughneck changing its name from “Roughneck Supplies, Inc.” to “Omnimmune Holdings, Inc.”, (iii) Roughneck changing its fiscal year end from May 31 to December 31 and (iv) Roughneck’s shareholders becoming the stockholders of the Company.

On August 7, 2008, Omnimmune Corp., a privately-held Texas corporation, merged with and into Omnimmune Acquisition Corp., a Delaware corporation, and a wholly-owned subsidiary of the Company formed for the purpose of the merger. As a result, (i) Omnimmune Corp. became a wholly-owned subsidiary of the Company, (ii) the shareholders of Omnimmune Corp. became the majority stockholders of the Company and the shareholders prior to the merger were reduced to a minority ownership, (iii) the historical management of the Company resigned, and the management of Omnimmune Corp. became the management of the Company, (iv) the business of Omnimmune Corp. became the business of Omnimmune and the former business of Roughneck was eliminated, and (v) the historical financial statements of Omnimmune Corp. became the historical financial statements of the Company. Therefore, as a consequence of two mergers, one on August 6, 2008, and one on August 7, 2008, Omnimmune (formerly Roughneck) went from being a public corporation domiciled in Nevada formerly in the business of marketing and retailing oil and gas drilling supply products with little or no continuing operations and a fiscal year end of May 31, to being a public company domiciled in Delaware in the biotechnology business with a fiscal year end of December 31. These transactions are described in detail in the Company’s Form 8-K filed with the SEC on August 12, 2008, as amended on August 21, 2008, August 27, 2008 and September 5, 2008, respectively.

Results of Operations

As a development stage pharmaceutical company, we produce no revenues and do not expect to produce any revenues for the foreseeable future. We have incurred operating losses of $378,429 and $1,460,253 for the three months ended March 31, 2009 and 2008, respectively, and as of March 31, 2009, we had an accumulated deficit of $19,716,428.

Because we produce no revenues, we rely entirely on debt and equity financing to fund ongoing operations, and expect to continue to do so for the foreseeable future. Generating revenues and ultimately achieving profitability will require the successful completion of our research and development programs, and the subsequent commercialization of the results or of products derived from such research and development efforts or from our patents and patents pending and those licensed from our strategic collaborators. No assurances can be given as to our ability to identify sufficient sources of funding to sustain our operations, commercialize our products or achieve profitability. These matters raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that may result from the outcome of this uncertainty. In order to alleviate our working capital deficiency and address our continued financing concerns, management intends to take affirmative steps towards identifying sources of capital that will be sufficient to fund our operations until such time as we are cash flow positive.

Table of Contents

Three Months Ended March 31, 2009 and March 31, 2008

Revenue

As a development stage pharmaceutical company, we produce no revenues and do not expect to produce any revenues for the foreseeable future.

Costs and Expenses

Our selling, general and administrative expenses decreased approximately 25% to $321,741 in the three months ended March 31, 2009, from $430,126 in the same period in 2008. For the three months ended March 31, 2008, selling, general, and administrative expenses increased primarily due to payroll and employee benefits of $134,750; license fees of $72,496; consulting fee of $62,850; legal and accounting fees of $30,921; non cash compensation of $10,399; and office rent expense of $2,320. The decrease in the selling, general and administrative expenses was the result of a reduction in legal fees, due to the completion of the reverse merger and the financings in the prior period.

Net Loss

For the reasons stated above, our net loss for the three months ending March 31, 2009 was $378,429 , compared to a net loss for the three months ending March 31, 2008 of $1,460,253. For the period since inception January 15, 1997 through March 31, 2009, our accumulated net loss is $19,716,428.

These losses, in addition to a lack of continuing operations, raises substantial doubt about our ability to continue as a going concern. Also, as of May 19, 2009, we had less than $5,000 of cash on hand. Accordingly, absent an immediate infusion of new capital, we will be unable to meet our ongoing obligations on a timely basis. Since we do not expect to generate significant revenues in the foreseeable future, we, in order to fund future operations, will be completely dependent on additional debt and equity financing arrangements to fund future operations.

Liquidity and Capital Resources

At March 31, 2009, we had a cash balance of $2,359 and less than $5,000 as of May 19, 2009. In the absence of substantial and immediate new funding, we will not have sufficient cash to fund our ongoing payment obligations to our employees, consultants, licensors, or other creditors. We have financed ourselves primarily through cash on hand and through loans from shareholders and investors in our bridge financings and private placement offerings. Subsequent activities have reduced the Company’s cash to less than $5,000.

Net cash flow used in operating activities was $57,667 for the three months ended March 31, 2009, compared to net cash flow used in operating activities of $302,391 for the same period in 2008. From inception through March 31, 2009, cash flows used in operating activities were $3,794,464.

Net cash provided by financing activities was $7,411 for the three months ended March 31, 2009, compared to $399,680 for the same period in 2008. From inception through March 31, 2009, we have generated $3,802,823 in cash from financing activities. We have financed our operations primarily through loans from shareholders and investors in our bridge financings and private placement equity offerings.

Management is seeking to raise additional money through private debt and equity offerings to enable us to satisfy our cash requirements in the coming months and beyond and to fund ongoing research and development activities. We are not self-supporting through internally generated capital, and rely exclusively on our continued ability to raise additional funds through private or public debt or equity financings to meet our ongoing cash needs.

We will require substantial additional funding in order to meet our obligations to our licensors, continue our research and product development programs, including preclinical testing and clinical trials of our product candidates, and meet ongoing operating expenses. We expect to continue to incur substantial losses through at least the next several years and may incur losses in subsequent periods. The amount and timing of our future losses are highly uncertain. Our ability to achieve and thereafter sustain profitability will be dependent upon, among other things, successfully developing, commercializing and obtaining regulatory approval or clearances for our technologies and products resulting from these technologies, which will require substantial additional funding, the availability of which is uncertain.

There is no assurance that we will obtain financing sufficient to pay ongoing obligations or to fund our working capital and other cash requirements. No assurance can be given that any such additional funding will be available or that, if available, can be obtained on terms favorable to us. If we are unable to raise needed funds on acceptable terms, we will not be able to develop or enhance our products, take advantage of future opportunities or respond to competitive pressures or unanticipated requirements. A material shortage of capital will require us to take drastic steps such as reducing our levels of operations, disposing of selected assets, curtailing our development efforts or seeking an acquisition partner. If cash is insufficient, we may not be able to continue operations.

Table of Contents

Off-Balance Sheet Arrangements

We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

Critical Accounting Policies

The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect our reported assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities.

We base our estimates and judgments on historical experience and on various other assumptions we believe to be reasonable under the circumstances. Future events, however, may differ markedly from our current expectations and assumptions. While there are a number of significant accounting policies affecting our consolidated financial statements; we believe the following critical accounting policy involves the most complex, difficult and subjective estimates and judgments:

Stock Based Compensation Effective January 1, 2006, the Company adopted SFAS No. 123 (revised), "Share-Based Payment" (SFAS 123(R)) utilizing the modified prospective approach. Prior to the adoption of SFAS 123(R) we accounted for stock option grant in accordance with APB Opinion No. 25, "Accounting for Stock Issued to Employees" (the intrinsic value method), and accordingly, recognized compensation expense for stock option grants.

A summary of option activity under the Plan as of March 31, 2009, and changes during the period ended are presented below:

	Number of Shares		Weighted Average Price Per Share
Outstanding at December 31, 2008		2,350,000	$	2.50
Granted		-		-
Exercised		-		-
Cancelled or expired		-		-
Outstanding at March 31, 2009		2,350,000	$	2.50
Exercisable at March 31, 2009		2,302,537	$	2.50
Not exercisable at March 31, 2009		47,463	$	2.50

Revenue Recognition . Our policy is to recognize revenue over the period that we perform required activities under the terms of various agreements. Revenue from transactions that do not require future performance obligations from us is recognized as contemplated in the agreements, typically upon acceptance and when collectability is reasonably assured. Revenue resulting from the achievement of milestone events stipulated in the agreements will be recognized when the milestone is achieved.

Research and Development. Research and development expenditures, including direct and allocated overhead expenses, are charged to expense as incurred.

Royalties . We are required to remit royalty payments based on product sales to certain parties under our license agreements. From time to time we have been in default under certain of our material license agreements with respect to our payment obligations and achievement of performance milestones; however, such license agreements are currently in good standing.

Long-Lived Assets . Equipment is stated at acquired cost less accumulated depreciation. Laboratory and office equipment are depreciated on the straight-line basis over the estimated useful lives (three to seven years).

Impairment of long-lived assets is recognized when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets may not be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment may be based upon appraisal, market value of similar assets or discounted cash flows.

Patent Costs and Rights . Patent costs and rights are expensed as incurred.

Income Taxes . As of March 31, 2009, we had aggregate unused net operating loss carryforwards of approximately $14,500,000. These carryforwards may be used to reduce future tax liabilities and expire at various dates through 2027. Our use of current net operating loss carryforwards may be substantially limited as a result of the change in ownership related to the Merger and the Offering.

Recent Accounting Pronouncements

For a summary of recently issued accounting standards, please see Note 1 to the consolidated unaudited financial statements included in Part I, Item 1 in this report.

Table of Contents

Cautionary Notice Regarding Forward Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”) and the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the current view about future events and financial performance based on certain assumptions. They include opinions, forecasts, projections, guidance, expectations, beliefs or other statements that are not statements of historical fact. In some cases, forward-looking statements can be identified by words such as “may,” “can,” “will,” “should,” “could,” “expects,” “hopes,” “believes,” “plans,” “anticipates,” “estimates,” “predicts,” “projects,” “potential,” “intends,” “approximates” or the negative or other variation of such terms and other comparable expressions. Forward-looking statements in this report may include statements about:

•	future financial and operating results, including projections of revenues, income, expenditures, cash balances and other financial items;

•	capital requirements and the need for additional financing;

•	our ability to develop commercially viable products;

•	our intellectual property rights and similar rights of others, including actual or potential competitors;

•	the outcome of regulatory submissions and approvals and clinical trials;

•	the performance of our future products and their potential to generate revenues;

•	our beliefs and opinions about the safety and efficacy of any of our future products and the results of our studies;

•	development of new products;

•	growth, expansion and acquisition strategies;

•	current and future economic and political conditions;

•	overall industry and market performance;

•	competition;

•	management’s goals and plans for future operations; and

•	other assumptions described in this report underlying or relating to any forward-looking statements.

The forward-looking statements in this report are only predictions. Actual results could and likely will differ materially from these forward-looking statements for many reasons, including the risks described under “Risk Factors” and elsewhere in this report. No guarantee about future results, performance or achievements can be made. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. The safe harbors for forward-looking statements provided by the Private Securities Litigation Reform Act are unavailable to issuers of “penny stock.” Our shares may be considered a penny stock and, as a result, the safe harbors may not be available to us.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.

CONTROLS AND PROCEDURES

As of March 31, 2009, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, Dr. Harris Lichtenstein. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2009 and December 31, 2008, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated, recorded, processed, summarized for management and reported within the time periods specified in the rules and forms of the SEC.

Table of Contents

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act are recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving our objectives and our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective at that reasonable assurance level. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the internal control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting identified in the evaluation that occurred during our first quarter of fiscal year 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

The Company may be subject to lawsuits, claims and other legal matters that arise in the ordinary course of conducting business, none of which, in management’s opinion, would be expected to have a material adverse impact on the Company’s financial condition, results of operations or cash flows.

ITEM 1A.

RISK FACTORS

An investment in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below and all other information contained in this report before deciding to invest in shares of our common stock. While all risks and uncertainties that we believe to be material to our business and, therefore, the value of our common stock are described below, it is possible that other risks and uncertainties that affect our business will arise or become material in the future. If we are unable to effectively address these risks and uncertainties, our business, financial condition or results of operations could be materially and adversely affected. In this event, the value of the common stock could decline and you could lose all or a portion of your investment.

Our auditors have substantial doubts as to our ability to continue as a going concern.

The auditor’s report on our financial statements for the year ended December 31, 2008 expresses an opinion that substantial doubt exists as to whether Omnimmune can continue to meet its ongoing obligations and remain in business. Because Omnimmune has been issued an opinion by its auditors that substantial doubt exists as to whether we can continue as a going concern, it may be more difficult for us to attract investors. Our future is dependent upon our ability to obtain financing and upon future profitable operations from the development and commercialization of our products. We may seek additional funds through private placements of equity or the incurrence of additional debt. Our financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event we cannot continue in existence.

We require additional financing, and an inability to raise the necessary capital or to do so on acceptable terms would threaten our ability to stay in business.

As of March 31, 2009, we had cash and cash equivalents of approximately $2,359, and that balance is less than $5,000 as of the date of this report. The Company has been unable to meet certain of its ongoing obligations, including payments due to consultants, noteholders, licensors and other creditors. Absent immediate additional infusions of capital, the Company does not have sufficient liquidity to meet its ongoing obligations on a timely basis, and must resort to consensual extensions and hope that creditors will refrain from pursuing default remedies with respect to delinquent obligations of the Company. The limited amount of cash on hand jeopardizes the Company’s ability to fund operations and satisfy its ongoing obligations in a timely manner, including to the licensors of its core technologies.

Table of Contents

We may seek to raise additional funds through public or private equity or debt financing, licensing and other agreements, a line of credit, asset sales or other arrangements. However, we cannot be sure that any additional funding, when needed, will be available on terms favorable to us or at all. Furthermore, any additional equity or equity-related financing may be dilutive to our stockholders, and debt financing, if available, may subject us to restrictive covenants and significant interest costs. We may also choose to obtain funding through licensing and other contractual arrangements. Such agreements may require us to relinquish our rights to certain of our technologies, products or marketing territories.

If we are unable to obtain additional capital, we may then attempt to preserve our available resources by various methods including deferring the satisfaction of commitments, reducing expenditures on our research and development programs or otherwise scaling back our operations. If we are unable to raise additional capital or defer costs, that inability would have a material adverse effect on our financial position, results of operations and prospects and our business could fail.

We are or soon may be past due under certain of our material license agreements with respect to our payment obligations. There is no assurance that we will receive extensions of these obligations or that we will not default under these agreements in the future; any such defaults could materially and adversely affect our business.

Each of our existing license agreements with third party collaborators require us to make periodic payments to the licensors for the licensed rights, including, by way of example, upfront and annual license maintenance fees, royalties based on product sales utilizing the licensed technology, sublicensing royalties, milestone payments based on certain achievements as we conduct trials on the licensed products and progress them through the FDA approval process, and the reimbursement or payment of costs associated with prosecuting the patents subject to these license agreements.

Given our significant cash flow limitations and our inability to raise additional capital, we have had difficulties making required milestone and other payments under certain of our license agreements, and we are delinquent with respect to certain of such payments, including OSU ($40,000 due March 2009) and IGR (€3000 due March 2009) and we are at significant risk of additional delinquencies with respect to forthcoming payments due under our license agreements. Although none of our licensors has declared a default under its respective license agreement, there is no certainty that such licensors will continue to refrain from calling a default under its license agreement or that we will have sufficient available funds with which to make such payment within the cure period if a default were called. If a default is called and we do not timely cure, the affected license agreement could be terminated.

There is also no assurance that we will be able to remain current in the payment of our license fees on a go-forward basis, or that the respective licensors will cooperate in any requests for waivers or extensions. All of the license agreements require the licensors to give written notice of any payment default, which would then commence a period of between 30 days and 90 days, depending on the particular license agreement, during which time the Company could cure the default. If we default in the payment of any of our obligations to our licensors, there is no assurance that we will be in a position to cure any such defaults during the particular cure period. In that event, the continued existence and/or exclusivity of the affected license could be at risk.

Additionally, our license agreements provide for various performance and achievement milestones to ensure that we devote adequate personnel and financial resources to the commercialization of the licensed patents and processes. If we do not achieve the milestones in our agreements with The Allegheny-Singer Research Institute and Columbia University, the respective licensor can, with prior notice and an opportunity to cure, elect to terminate the subject license agreement or convert the exclusive worldwide license to a non-exclusive license. With respect to our license agreement with The Institute Gustave Roussy, we have until November 1, 2010 to achieve net sales or sublicense revenue from products developed with the licensed patents, after which time the licensed rights will become non-exclusive; however, we can request two one-year extensions of the exclusive license with the payment of an additional license fee to the licensor. Our agreement with OSU provides that the parties can mutually agree to extend the performance milestones so long as the delay is not a result of lack of capital for development on our part.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

For more information about unregistered sales of our securities, see Item 1, Note 8 of this report for a discussion of our sales of convertible promissory notes and Units.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5.

OTHER INFORMATION

None.

Table of Contents

ITEM 6.

EXHIBITS

EXHIBIT NO.		NAME OF EXHIBIT
2.1		Agreement of Merger, dated as of August 6, 2008, by and between Roughneck Supplies, Inc. and Omnimmune Holdings, Inc. (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on August 12, 2008).
2.2		Agreement of Merger and Plan of Reorganization, dated as of August 7, 2008, by and among the Omnimmune Holdings, Inc., Omnimmune Acquisition Corp., a wholly owned subsidiary of the Company, and Omnimmune Corp. (incorporated by reference to Exhibit 2.2 to our Current Report on Form 8-K filed on August 12, 2008).
2.3		Certificate of Merger, effective August 6, 2008, merging Roughneck Supplies, Inc. with and into Omnimmune Holdings, Inc. (incorporated by reference to Exhibit 2.3 to our Current Report on Form 8-K filed on August 12, 2008).
2.4		Articles of Merger, effective August 7, 2008, merging Omnimmune Corp. with and into Omnimmune Acquisition Corp. (incorporated by reference to Exhibit 2.4 to our Current Report on Form 8-K filed on August 12, 2008).
4.1		Second Amended and Restated Convertible Demand Promissory Note
10.1		Registration Rights Agreement, dated as of August 7, 2008, by and among Omnimmune Holdings, Inc. and the stockholders of Omnimmune Holdings, Inc. parties thereto (incorporated by reference to Exhibit 10.15 to our Current Report on Form 8-K filed on August 12, 2008).
10.2		Form of Lock-Up Agreement between the Company and executive officers and certain stockholders (incorporated by reference to Exhibit 10.18 to our Current Report on Form 8-K filed on August 12, 2008).
10.3		Amendment and Pledge dated July 31, 2008, to Gift Agreement entered into as of April 18, 2008, by and among The Ohio State University Medical Center, The Ohio State University Foundation and Omnimmune Corp. (incorporated by reference to Exhibit 10.23 to our Current Report on Form 8-K filed on August 12, 2008).
31.1		Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Chief Executive Officer Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		OMNIMMUNE HOLDINGS, INC.

Dated: May 20, 2009		/s/ HARRIS A. LICHTENSTEIN
		Harris A. Lichtenstein
		Chief Executive Officer

Table of Contents

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

OMMH Omnimmune Holdings Inc (CE)